
Genovis Q2 2024 - Focusing fully on the enzyme business

Redeye updates its view on Genovis following the Q2 report and the announced divestment of its antibody business. As a consequence, we have revised our model to reflect lower sales projections and adjusted our fair value range accordingly. However, we believe the 21% decline on the report day was an overreaction and with the share trading in bear case territory R/R looks attractive.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Genovis Q2 2024 - Focusing fully on the enzyme business](#)